Delving into the Latest Updates on KAEL-GemVax Co., Ltd. with Synapse

Overview

Tags

Neoplasms

Digestive System Disorders

Nervous System Diseases

Therapeutic vaccine

Synthetic peptide

Synthetic peptide vaccine

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	3
Endocrinology and Metabolic Disease	1
Immune System Diseases	1
Nervous System Diseases	1

Top 5 Drug Type	Count

Therapeutic vaccine	2
Synthetic peptide	1
Synthetic peptide vaccine	1

Top 5 Target	Count

Mitochondrial proteins	1
TERT(Telomerase reverse transcriptase)	1

This study involves testing of the medicine LTX-315 combined with a cancer vaccine (GV1001). This will be tested in patients that have had surgery with curative intent for malignant tumour.
GV1001 is a peptide vaccine in development to treat cancer. An adjuvant, is required to start the immune response in the body to have effect of GV-1001.
LTX-315, also a peptide, in development for cancer treatment. In this study, the investigators wish to find out whether LTX-315 can make GV1001 more effective at stimulating the immune system.

Start Date01 Aug 2010

Sponsor / Collaborator

Lytix Biopharma AS

[+1]

NCT00514072

/ Unknown statusPhase 2

A Double-Blind Randomized Phase 2.5 Trial of ONY-P1 Vaccine Versus Placebo in Men With D0 Prostate Cancer Following Limited Androgen Ablation

RATIONALE: Vaccines made from tumor cells may help the body build an effective immune response to kill tumor cells.
PURPOSE: This randomized phase II trial is studying vaccine therapy to see how well it works compared with a placebo in treating patients with stage D0 prostate cancer.

Start Date01 Mar 2007

Sponsor / Collaborator

KAEL-GemVax Co., Ltd.

[+1]

100 Clinical Results associated with KAEL-GemVax Co., Ltd.

Login to view more data

0 Patents (Medical) associated with KAEL-GemVax Co., Ltd.

Login to view more data

3

Literatures (Medical) associated with KAEL-GemVax Co., Ltd.

01 Jul 2016·NeuroToxicologyQ2 · MEDICINE

Neural stem cells injured by oxidative stress can be rejuvenated by GV1001, a novel peptide, through scavenging free radicals and enhancing survival signals

Q2 · MEDICINE

Article

Author: Lee, Young Joo ; Lee, Eun-Hye ; Lee, Kyu-Yong ; Choi, Na-Young ; Yoon, Moon-Young ; Kim, Gabseok ; Park, Hyun-Hee ; Kim, Sangjae ; Koh, Seong-Ho ; Yu, Hyun-Jung

Oxidative stress is a well-known pathogenic mechanism of a diverse array of neurological diseases, and thus, numerous studies have attempted to identify antioxidants that prevent neuronal cell death. GV1001 is a 16-amino-acid peptide derived from human telomerase reverse transcriptase (hTERT). Considering that hTERT has a strong antioxidant effect, whether GV1001 also has an antioxidant effect is a question of interest. In the present study, we aimed to investigate the effects of GV1001 against oxidative stress in neural stem cells (NSCs). Primary culture NSCs were treated with different concentrations of GV1001 and/or hydrogen peroxide (H2O2) for various time durations. The H2O2 decreased the viability of the NSCs in a concentration-dependent manner, with 200μM H2O2 significantly decreasing both proliferation and migration. However, treatment with GV1001 rescued the viability, proliferation and migration of H2O2-injured NSCs. Consistently, free radical levels were increased in rat NSCs treated with H2O2, while co-treatment with GV1001 significantly reduced these levels, especially the intracellular levels. In addition, GV1001 restored the expression of survival-related proteins and reduced the expression of death-associated ones in NSCs treated with H2O2. In conclusion, GV1001 has antioxidant and neuroprotective effects in NSCs following treatment with H2O2, which appear to be mediated by scavenging free radicals, increasing survival signals and decreasing death signals.

01 Jun 2014·Annals of the Rheumatic Diseases

AB0125 The Effect of Gv1001, A Peptide Vaccine, in Animal Model of Rheumatoid Arthritis

Author: J.S. Kim ; J.Y. Choi ; E.Y. Lee ; S.-Y. Oh ; S. Kim ; I.A. Choi

Background GV1001 is a 16-mer peptide developed as a cancer vaccine to prime the immune system to recognize telomerase. Besides its role as a cancer vaccine, GV1001 has anti-inflammatory effects in in-vitro experiments using macrophage or monocyte. Objectives We evaluated the effect of GV1001 to inhibit joint inflammation in animal model of RA. Methods 5-week old BDA/1 mice were used to induce collagen induced arthritis (CIA). Mice were immunized with bovine type II collagen on day 1 and boosted on day 21. Treatments with GV1001 (0.2 nM, 1 nM, 2 nM, 5 nM, and 10 nM) or placebo were started on day 21, three times in alternative week (on day 21, 23, 25 and day 35, 37, 39). Weight and arthritis index of the mice using a standardized grading scale (0–3) were monitored from day 21. Observation finished on day 42, harvesting mouse serum and joints for further analysis. Histological scores of joint damage were assessed using 0–3 grading scale. Results Mean arthritis index on day 42 was lower in 0.2 nM GV1001 group compared to placebo group without statistical significance (p=0.1). Histologic assessment after low dose GV1001 treatment showed a tendency to have a lower histologic score (Fig. 1). Serum IL-6 level was significantly lower in 1 nM (the same concentration used as human cancer vaccine) and 0.2 nM GV1001 group (p Conclusions In this study, we explored the novel therapeutic effect of GV1001 in animal model of rheumatoid arthritis. Protective effect of GV1001 was not dose dependent and effective in 1 nM, which is the same concentration used as human cancer vaccine and the lower dose as 0.2 nM. These results suggest the therapeutic potential of GV1001 as a new RA treatment. Disclosure of Interest I. A. Choi: None declared, J. Y. Choi: None declared, J. S. Kim: None declared, S.-Y. Oh Employee of: KAEL-GemVax, developer of GV1001, S. Kim Shareholder of: KAEL-GemVax, developer of GV1001, E. Y. Lee: None declared DOI 10.1136/annrheumdis-2014-eular.2421

01 Jun 2014·Neurobiology of AgingQ2 · MEDICINE

The novel vaccine peptide GV1001 effectively blocks β-amyloid toxicity by mimicking the extra-telomeric functions of human telomerase reverse transcriptase

Q2 · MEDICINE

Article

Author: Kim, Sangjae ; Lee, Young Joo ; Koh, Seong-Ho ; Lee, Jessica Woojin ; Lee, Kyu-Yong ; Lee, Eun-Hye ; Park, Hyun-Hee ; Lee, Sang-Hun ; Choi, Na-Young

GV1001 is a 16-amino-acid vaccine peptide derived from the human telomerase reverse transcriptase sequence. We investigated the effects of GV1001 against β-amyloid (Aβ) oligomer-induced neurotoxicity in rat neural stem cells (NSCs). Primary culture NSCs were treated with several concentrations of GV1001 and/or Aβ₂₅₋₃₅ oligomer for 48 hours. GV1001 protected NSCs against the Aβ₂₅₋₃₅ oligomer in a concentration-dependent manner. Aβ₂₅₋₃₅ concentration dependently decreased viability, proliferation, and mobilization of NSCs and GV1001 treatment restored the cells to wild-type levels. Aβ₂₅₋₃₅ increased free radical levels in rat NSCs while combined treatment with GV1001 significantly reduced these levels. In addition, GV1001 treatment of Aβ₂₅₋₃₅-injured NSCs increased the expression level of survival-related proteins, including mitochondria-associated survival proteins, and decreased the levels of death and inflammation-related proteins, including mitochondria-associated death proteins. Together, these results suggest that GV1001 possesses neuroprotective effects against Aβ₂₅₋₃₅ oligomer in NSCs and that these effects are mediated through mimicking the extra-telomeric functions of human telomerase reverse transcriptase, including the induction of cellular proliferation, anti-apoptotic effects, mitochondrial stabilization, and anti-aging and anti-oxidant effects.

100 Deals associated with KAEL-GemVax Co., Ltd.

Login to view more data

100 Translational Medicine associated with KAEL-GemVax Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 27 Jan 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 2 Clinical

2

1

Approved

Other

4

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Tertomotide hydrochloride ( TERT )	Pancreatic Cancer More	Approved
Ruxotemitide ( Mitochondrial proteins )	Sarcoma More	Phase 2
MSI-vaccine(KAEL-GemVax)	Colorectal Cancer More	Phase 2
HIV vaccines polytope(KAEL-GemVax Co., Ltd.)	HIV Infections More	Discontinued
GV-1002	Pancreatic Cancer More	Pending